Robotic Bronchoscopy Revolutionizes Early Lung Cancer Detection in Landmark Study

A five-year study by the Mayo Clinic has confirmed the effectiveness of robotic-assisted bronchoscopy in detecting lung cancer. The technology, now used in over 500 clinics globally, offers high accuracy and low complication rates. Its precision in navigating airways and sampling nodules could transform early diagnosis and treatment. The study focused on shape-sensing robotic bronchoscopy, which demonstrated an 85% sensitivity in identifying malignant lung lesions. Of the samples analysed, 56% were confirmed cancerous, while 21% were benign. The procedure's diagnostic accuracy reached nearly 77% under standardised national guidelines.

Complications occurred in just 2.8% of cases, reinforcing the method's safety. Clinicians can now access difficult-to-reach areas of the lungs, collecting multiple tissue samples in a single session. Integration with Cone-Beam-CT, as seen in systems like the Monarch Platform, further enhances targeting precision. Beyond diagnosis, the technology supports immediate treatment through paired modalities such as pulsed electric field ablation (PEF). This allows patients to undergo biopsy and therapy under one anaesthetic, reducing delays. The addition of endobronchial ultrasound (EBUS) also improves staging by sampling mediastinal lymph nodes. Early detection remains critical, as five-year survival for localised lung cancer stands at 67%, compared to just 12% once metastasis occurs. With around 1.6 million suspicious nodules found annually in US screening programs, the demand for reliable diagnostic tools is high.

Robotic bronchoscopy has become a standard in many hospitals since its FDA clearance in 2019. Its high detection rates, minimal risks, and ability to combine diagnosis with treatment offer clear advantages. As adoption grows, the technology could play a key role in reducing lung cancer mortality through earlier intervention.